Therapeutic Asset Ratings

374 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
68Ga-NNS309 Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P1	C (36)
mgy825 Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P1	C (36)
nir178 Renal Cell Carcinoma	Novartis Pharmaceuticals	P2	D (30)
4-((3-Acetamidophenyl)amino)-N-cyclopropyl-2-((2-fluoro-4-iodophenyl)amino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor	Novartis Pharmaceuticals		D (30)
Evolocumab Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals		D (30)
Ezetimibe Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals	N/A	D (30)
Humax-Cd20 Pregnancy Disorder	Novartis Pharmaceuticals		D (30)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Familial Mediterranean Fever	Novartis Pharmaceuticals		D (30)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Cryopyrin-Associated Periodic Syndrome	Novartis Pharmaceuticals		D (30)
Rosuvastatin Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals		D (30)
Tafinlar BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor	Novartis Pharmaceuticals		D (30)
Tisagenlecleucel B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma	Novartis Pharmaceuticals		D (30)
Zolgensma Spinal Muscular Atrophy	Novartis Pharmaceuticals		D (30)
Gonadotropin-Releasing Hormone Breast Neoplasms	Novartis Pharmaceuticals		D (28)
Lutetium Vipivotide Tetraxetan Metastatic Prostate Carcinoma	Novartis Pharmaceuticals		D (28)
IANALUMAB Non-Hodgkin Lymphoma	Novartis Pharmaceuticals	P1	D (23)
nio752 Supranuclear Palsy, Progressive, 1	Novartis Pharmaceuticals	P3	NR (0)
oav101 Spinal Muscular Atrophy, Type II	Novartis Pharmaceuticals	P3	NR (0)
Octreotide Pamoate Somatostatin Receptor Positive (SSTR+)	Novartis Pharmaceuticals	P3	NR (0)
kfa115 Colorectal Carcinoma	Novartis Pharmaceuticals	P1	NR (0)
amo959 Castration-Resistant Prostate Carcinoma	Novartis Pharmaceuticals	P1/2	NR (0)
dft383 Nephropathic Cystinosis	Novartis Pharmaceuticals	P1/2	NR (0)
jsb462 Metastatic Prostate Carcinoma	Novartis Pharmaceuticals	P1/2	NR (0)
tno155 Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P1/2	NR (0)

Showing 351 to 374 of 374 assets

PreviousPage 15 of 15Next